What's behind AbbVie's latest 2.3% stock pullback?

Traders Union
All News
Stocks
Abbvie slides 2.28% today on pressure

Highlights

AbbVie completed the Apogee Therapeutics acquisition, bringing zumilokibart into its portfolio and expanding its immunology pipeline.
Second-quarter 2026 net revenues grew 10.2% year-over-year to $16.99 billion, with Skyrizi and Rinvoq sales up 24% and 25%.
Shares of AbbVie trade below key short-term averages, with sideways consolidation expected between $243.36 and $254.72 over the next five sessions.

Rising new drug sales and updated guidance fail to offset sector pressure

AbbVie completed its acquisition of Apogee Therapeutics, adding zumilokibart to its portfolio. The company reported second-quarter 2026 net revenues of $16.99 billion and adjusted earnings per share of $3.65, reflecting 10.2% revenue growth year-over-year. Product sales for Skyrizi and Rinvoq increased by 24% and 25%, respectively, partially countering Humira declines from biosimilar competition. AbbVie updated its third-quarter 2026 earnings guidance to $3.84–$3.88 EPS and announced a quarterly dividend of $1.73 per share, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, notes ABBV's strong Q2 performance but highlights persistent technical weakness. He sees price action under pressure below key moving averages and warns that gains from acquisitions are not offsetting broad selling. Sentiment remains mixed, with oscillators diverging and sellers dominant in the short term. Despite positive momentum indicators, he believes downside risks are real as sellers may retest lower support. "Fundamentals are solid, but the technical structure signals caution and potential further weakness until resistance is reclaimed," Kharitonov says.

Viktoras Karapetjanc, expert at Traders Union, views AbbVie’s revenue growth and the Apogee Therapeutics acquisition as key drivers of future upside. He highlights strong gains in Skyrizi and Rinvoq, calling the pipeline reshuffle a positive for earnings visibility. Market volatility appears to be presenting opportunity rather than threat, in his view. "The bullish structure remains intact — further growth is expected as new therapies come online and guidance strengthens," Karapetjanc says.

Sholanke Dele, market strategist, sees broad selling pressure limiting short-term recovery in ABBV. He notes the downside gap and mixed technical signals, viewing near-term risks as elevated despite positive news flow. Macro headwinds and continued competition weigh on sentiment. "Investors should stay defensive until momentum and technicals turn decisively in favor of buyers," Dele warns.

Near-term bearish setup as oscillators diverge from bullish momentum

AbbVie trades below its 20-day and 50-day moving averages at $257.52 and $254.47, but remains above the 200-day at $228.34. This structure highlights prevailing near-term pressure from sellers and medium-term caution, while the long-term trend is still bullish. Immediate resistance sits at the Ichimoku Kijun level at $254.08, with support at $249.08. Momentum indicators from MACD and ADX are positive, showing underlying strength. The RSI is neutral at 50.1 with a buy forecast, while Stochastic RSI is oversold and the CCI is neutral. Bull/Bear Power remains above zero, reflecting buyer activity but also an oversold environment. The Awesome Oscillator supports the bullish bias. The intraday tone is pressured after a downside gap at the open, and several oscillators diverge from momentum, confirming mixed short-term signals.

Previously it was reported that AbbVie's outlook was tied to resolving key technical resistance amid ongoing acquisition activity and pipeline developments. The current price action confirms continued near-term pressure despite positive earnings growth, with traders advised to monitor $254.08 as a pivotal level for any potential upside breakout.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.